View Item 

Show simple item record

Anticoagulation Management in Patients With Atrial Fibrillation and Cirrhosis
dc.contributor.authorShenoy, Abhishek
dc.contributor.authorJarava, David
dc.contributor.authorStotts, Matthew J.
dc.contributor.authorIntagliata, Nicolas M.
dc.date.accessioned2021-05-12T17:26:48Z
dc.date.available2022-05-12 13:26:47en
dc.date.available2021-05-12T17:26:48Z
dc.date.issued2021-04
dc.identifier.citationShenoy, Abhishek; Jarava, David; Stotts, Matthew J.; Intagliata, Nicolas M. (2021). "Anticoagulation Management in Patients With Atrial Fibrillation and Cirrhosis." Clinical Liver Disease (4): 277-281.
dc.identifier.issn2046-2484
dc.identifier.issn2046-2484
dc.identifier.urihttps://hdl.handle.net/2027.42/167535
dc.publisherWiley Periodicals, Inc.
dc.titleAnticoagulation Management in Patients With Atrial Fibrillation and Cirrhosis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGastroenterology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167535/1/cld1048.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167535/2/cld1048_am.pdf
dc.identifier.doi10.1002/cld.1048
dc.identifier.sourceClinical Liver Disease
dc.identifier.citedreferenceEliquis (Apixaban) Package Insert. Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf.
dc.identifier.citedreferenceKuo L, Chao TF, Liu CJ, et al. Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Heart Assoc 2017; 6: e005307.
dc.identifier.citedreferenceChokesuwattanaskul R, Thongprayoon C, Bathini T, et al. Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta‐analysis. Dig Liver Dis 2019; 51: 489 ‐ 495.
dc.identifier.citedreferenceAnsell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest 2008; 133 ( Suppl. 6 ): 160S ‐ 198S.
dc.identifier.citedreferenceLee SJ, Uhm JS, Kim JY, et al. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol 2015; 180: 185 ‐ 191.
dc.identifier.citedreferenceChoi J, Kim J, Shim JH, et al. Risks versus benefits of anticoagulation for atrial fibrillation in cirrhotic patients. J Cardiovasc Pharmacol 2017; 70: 255 ‐ 262.
dc.identifier.citedreferenceIntagliata NM, Maitland H, Caldwell SH. Direct oral anticoagulants in cirrhosis. Curr Treat Options Gastroenterol 2016; 14: 247 ‐ 256.
dc.identifier.citedreferencePollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511 ‐ 520.
dc.identifier.citedreferenceIntagliata NM, Maitland H, Pellitier S, et al. Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: a step forward. Liver Transpl 2017; 23: 396 ‐ 397.
dc.identifier.citedreferenceSiegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413 ‐ 2424.
dc.identifier.citedreferenceIntagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 2016; 61: 1721 ‐ 1727.
dc.identifier.citedreferenceHoolwerf EW, Kraaijpoel N, Buller HR, et al. Direct oral anticoagulants in patients with liver cirrhosis: a systematic review. Thromb Res 2018; 170: 102 ‐ 108.
dc.identifier.citedreferenceHum J, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017; 98: 393 ‐ 397.
dc.identifier.citedreferenceSerper M, Weinberg EM, Cohen JB, et al. Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation. Hepatology 2020. Available at: https://doi.org/10.1002/hep.31264.
dc.identifier.citedreferenceWarfarin Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf.
dc.identifier.citedreferencePradaxa (Dabigatran) Package Insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf.
dc.identifier.citedreferenceEdoxaban Prescribing Information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
dc.identifier.citedreferenceLip GY. Implications of the CHA(2)DS(2)‐VASc and HAS‐BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124: 111 ‐ 114.
dc.identifier.citedreferenceXarelto (Rivaroxaban) Package Insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202439s017lbl.pdf.
dc.identifier.citedreferenceRahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014; 11: 639 ‐ 654.
dc.identifier.citedreferenceNalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J 2016; 37: 1565 ‐ 1572.
dc.identifier.citedreferenceLee H, Choi EK, Rhee TM, et al. Cirrhosis is a risk factor for atrial fibrillation: a nationwide, population‐based study. Liver Int 2017; 37: 1660 ‐ 1667.
dc.identifier.citedreferenceHuang WA, Dunipace EA, Sorg JM, et al. Liver disease as a predictor of new‐onset atrial fibrillation. J Am Heart Assoc 2018; 7: e008703.
dc.identifier.citedreferenceCaldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039 ‐ 1046.
dc.identifier.citedreferenceIntagliata NM, Caldwell SH. Changes in hemostasis in liver disease. J Hepatol 2017; 67: 1332 ‐ 1333.
dc.identifier.citedreferenceLip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor‐based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263 ‐ 272.
dc.identifier.citedreferencePisters R, Lane DA, Nieuwlaat R, et al. A novel user‐friendly score (HAS‐BLED) to assess 1‐year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093 ‐ 1100.
dc.identifier.citedreferenceGranger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981 ‐ 992.
dc.identifier.citedreferenceConnolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139 ‐ 1151.
dc.identifier.citedreferenceInvestigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499 ‐ 2510.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cld1048.pdf
Size:
138.7KB
Format:
PDF
View/Open
Name:
cld1048_am.pdf
Size:
311.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.